Cellgram CKD(Cellgram CKD) - _专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

Allogeneic bone marrow-derived mesenchymal stem cell therapy

靶点-

作用机制

细胞凋亡抑制剂、细胞替代物

治疗领域

泌尿生殖系统疾病

在研适应症-

非在研适应症

勃起功能障碍

原研机构

Pharmicell Co., Ltd.

在研机构-

非在研机构

Pharmicell Co., Ltd.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Cellgram CKD 相关的临床试验

NCT05096182 / Active, not recruitingN/A

Long-term Follow-up of Patients With Chronic Kidney Disease Who Had Administered Cellgram-CKD in PMC-P-12 Study

This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov.Identifier: NCT05042206).

开始日期2022-03-10

申办/合作机构

Pharmicell Co., Ltd.

NCT05042206 / Completed临床1期

An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease

This clinical trial is an open, single-center, phase 1 clinical trial to evaluate the safety of allogeneic bone marrow-derived mesenchymal stem cell injection in patients with chronic kidney disease.
The purpose is to evaluate the safety for 12 months after administration of Cellgram-CKD 3 times in 10 patients with chronic kidney disease.

开始日期2021-11-24

申办/合作机构

Pharmicell Co., Ltd.